选择性5-羟色胺回收抑制剂治疗焦虑和抑郁障碍共病临床研究

目的探讨选择性5羟色胺回收抑制剂(SSRIs)对焦虑和抑郁障碍共病的疗效。方法对符合DSM-IV诊断标准的25例焦虑和抑郁障碍共病患者(共病组)和30例抑郁症患者(抑郁组)使用SS-RIs治疗6周,对所有病例在治疗前、治疗第2,4,6周末评定HAMD和HAMA。结果SSRIs对两组患者治疗效果良好,从第2周开始,两组患者的HAMD和HAMA评分均显著下降,6周末的治疗有效率(分别为80.0%,86.7%)和临床治愈率(分别为48.0%,53.3%)相似。共病组联用抗焦虑药的人数(76.0%)显著多于抑郁组(P<0.05)。结论SSRIs治疗焦虑和抑郁障碍共病患者有效。

A control study of SSRIs in the treatment of patients with comorbid anxiety and depression (CAD)

ObjectiveTo explore the efficacy of selective serotonin reuptake inhibitors(SSRIs) in the treatment of patients with comorbid anxiety and depression (CAD).Methods25 patients who met both major depression and generalized anxiety disorder(or panic disorder) in DSM-IV (CAD group) and 30 patients who only met major depression in DSM-IV( depression group) were investigated. All patients were treated by SSRIs and were measured by HAMD and HAMA in the baseline, 2 weekend, 4 weekend and 6 weekend. ResultsThe efficacy rates of two groups were similarly.There were no significant differences in the effective power and clinical recovery rate. There were more people who used antianxietic drugs in the CAD group than in the depression group (P<0.05). ConclusionSSRIs is an effective and safe antidepressant in the treatment of patients with comorbid anxiety and depression (CAD).